Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir for RSV in HSCT Recipients
NCT04056611Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Who Developed Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI). Started Dec 2019; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04056611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056611.